EPIK-P1: Retrospective Chart Review Study of Patients (pts) With PIK3CA-Related Overgrowth Spectrum (PROS) Who Have Received Alpelisib (ALP) as Part of a Compassionate Use Programme
G. Canaud, et al.
The real-world evidence from the EPIK-P1 study demonstrates that ALP confers clinically meaningful efficacy to, and is well tolerated in, pts with PROS.
Interim results from a phase 2 study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies
R. Aggarwal, et al.
We observed anti-tumor activity with single agent ceralasertib in ARID1A-deficient solid tumors, including two patients with durable and ongoing complete responses. Accrual is ongoing in stage 2 using absence of BAF250a expression by IHC for patient selection.
A phase 1/2 multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors
M.L. Johnson, et al.
DS-7300 was generally well tolerated with early signs of clinical activity, including objective responses, in pts with pretreated advanced solid tumors. Expansion cohorts are currently enrolling to evaluate DS-7300 in selected tumor types.
An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors
J. Rodon, et al.
SKB264 has demonstrated encouraging safety and antitumor activity. Study continues to identify dose(s) of SKB264.